Skip to content

Impact of Resveratrol on Brain Function and Structure

Impact of Resveratrol on Brain Function and Structure

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02621554
Enrollment
60
Registered
2015-12-03
Start date
2016-04-30
Completion date
2017-01-31
Last updated
2017-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

Memory, Resveratrol, elderly, cognition

Brief summary

The study will investigate whether resveratrol could provide positive effects on memory and brain structures and functions in healthy elderly participants.

Detailed description

Cell and animal studies postulated various beneficial effects of resveratrol, ranging from a reduction of inflammatory processes and the treatment of cancer to the prevention of cardiovascular diseases and stroke. With regard to cognitive decline, rodent models for Alzheimer's disease (AD) showed improved learning and decelerated hippocampal neurodegeneration after intake of resveratrol. Animal and first human studies provided evidence that resveratrol might serve as an easy, cost-effective option to develop novel prevention and treatment strategies against age-associated cognitive decline. To test this hypothesis, the researchers study general brain structure and function on healthy older individuals (\> 60years old).

Interventions

DIETARY_SUPPLEMENTresveratrol supplementation

6 months of resveratrol supplementation

DIETARY_SUPPLEMENTPlacebo

6 months of placebo intake

Sponsors

University of Leipzig
CollaboratorOTHER
Evolva SA
CollaboratorINDUSTRY
Max Planck Institute for Human Cognitive and Brain Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* subjects who are healthy or with subjective memory complaints * older than 60 years old * normal to overweight participants (BMI: 22-40 kg/sqm)

Exclusion criteria

* dementia * Psychiatric diseases * severe untreated internal diseases * diabetes * younger than 60 years * BMI \< 22 or \>40

Design outcomes

Primary

MeasureTime frame
Change from baseline Verbal Learning Task Scores at 6 monthsBaseline (timepoint 0), after 6 months (timepoint 6 months)

Secondary

MeasureTime frame
Change from baseline Verbal Learning Task Scores at 12 monthsafter 12 months (timepoint 12 months)
Mini Mental State ExaminationBaseline (timepoint 0), after 6 months (timepoint 6 months) and after 12 months (timepoint 12 months)
Structural changes on the brain MRI imagesBaseline (timepoint 0), after 6 months (timepoint 6 months) and after 12 months (timepoint 12 months)
Functional changes on the brain MRI imagesBaseline (timepoint 0), after 6 months (timepoint 6 months) and after 12 months (timepoint 12 months)
Plasma biomarkersBaseline (timepoint 0), after 6 months (timepoint 6 months) and after 12 months (timepoint 12 months)

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 7, 2026